– CNBC
William Blair Initiates Coverage On NewAmsterdam Pharma with Outperform Rating
William Blair analyst Matthew Phipps initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform rating.
Related Posts
Data Storage Company Seagate’s Q1 Earnings Miss Estimates With Pressured Margins; May Report Loss In Q2
Seagate Technology Holdings PLC (NASDAQ: STX) reported Q1 revenues of $1.454 billion, missing the analyst consensus of $1.530 billion.
5,198 ETH Worth $10M Was Just Burned
What happened: On Sunday a total of 5,198.18 Ether (CRYPTO: ETH) worth $10,456,441, based on the current value of Ethereum at time of publication ($2,011.56), was burned from Ethereum transactions.
The Latest Analyst Ratings for Franklin Resources
Franklin Resources (NYSE:BEN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…